CRISIL assigns Nureca at CRISIL BB+
Nureca (NSE: NURECA) said CRISIL has assigned its credit rating at CRISIL BB+. The company is valued at about ₹291 crore.
What happened
Nureca (NSE: NURECA) informed the stock exchanges on 3 November 2026 at 04:36 PM that CRISIL has assigned its credit rating at CRISIL BB+.
Company snapshot
Nureca is a micro-cap company, with a market value of about ₹291 crore.
The stock last traded at ₹305, against a 52-week range of ₹204–₹376 (18.9% below the high).
Before this filing the shares had moved −18.6% over the month and −13.1% over three months. Average daily turnover over the last 20 sessions was about ₹0.16 crore.
Promoters held 70.68% at the end of Q2 FY27, up 2.59% points from the previous quarter. Foreign institutions owned 0.22% and domestic institutions 0.24%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 72 | 4.4 | 4.44 |
| Q3 FY26 | 40 | 3.7 | 3.91 |
| Q4 FY26 | 35 | -6.1 | -6.45 |
| Q1 FY27 | 40 | 3.1 | 3.21 |
| Q2 FY27 | 59 | 4.1 | 4.25 |
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Market-wide, 1,381 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.0%, with 46% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
- Nureca Ltd. Estimates – NSE:NURECA
- Nureca posts highest quarterly revenue in five years, Q2 sales jump 55%
- Nureca Q2FY27 Results: Revenue up 55% YoY to ₹58.53 crore, 20-quarter high
- Nureca Q2 Profit Rises to Rs 40.51 Million; Revenue Up 55%
- Nureca (NURECA.NS) Pulls Back -2.37% From ₹328.91 Resistance 2026-10-20 - Dividend Stock Picks
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.